Boom Capital

Boom Capital Research Investment Thesis Boom Capital invests early in founders building at the frontiers of science. The firm positions founders as "scientist-protagonists" and focuses on breakthrough innovations in frontier sectors including genomics, machine intelligence, aerospace, new chemistries, and adjacent deep science areas. Solo GP Celestine Schnugg specifically treats technical founders with scientific rigor as the protagonists of breakthrough ventures, seeking to back underrepresented leaders tackling non-obvious, ambitious scientific problems. Founder Preferences and Investment Approach Boom Capital prioritizes: Highly technical, science-based founders with deep domain expertise Teams tackling high technical and market risk problems Underrepresented leaders in frontier science Early-stage founders building durable science companies Celestine Schnugg is known for being the first institutional investor in portfolio companies including Mammoth Biosciences, A-Alpha Bio, and Fauna Bio, demonstrating a pattern of early conviction in exceptional scientific teams. Portfolio and Investment Focus Boom Capital maintains a 12-company portfolio with proven conviction across: Life Sciences & Biotech (Primary Focus) Fauna Bio: Synthetic biology for genetic interventions Bioptimus: AI foundation models for biological research (Series A, $76M+ raised) Shiok Meats: Lab-cultured seafood (Series A, $30.7M+ raised) Monod: Biosensors and protein detection platforms (Seed, $25M+ raised) Bioloomics: Target-degrading antibodies (Seed, $8.7M raised) Harmonic Discovery: Biosensor platform (Seed, $8M+ raised) Endpoint Health: Healthcare automation (Seed, $52M+ raised) Machine Intelligence & AI Synthesis: Computer vision AI models (Seed, $17M+ raised) Olio Labs: Cellular biology AI platform (Series A, $4.5M+ raised) Samaya AI: Medical AI applications Aerospace & Space Impulse Space: Orbital transportation and logistics (first investor, portfolio company) Merlin Labs: Autonomous aerospace systems Astra: Rocket systems (pre-series exit) SpaceX: Early belief (exited via IPO trajectory) Healthcare & Related Diligent Robots: Autonomous healthcare material handling robots (Series C, $99.9M+ raised) Nabla Bio: Biotech platform Vitra Bio: Cellular health (portfolio company) Stage Focus and Check Sizes Boom Capital primarily invests at early stages: Seed : 7 investments (average round: $9.55M) Series A : 3 investments (average round: $18.5M) Series B : 1 investment (average round: $30M) Series C : 1 investment (average round: $52M) Typical Check Size : $50,000 - $300,000 (per F4-OS data) Despite small check sizes, Boom leads rounds and maintains conviction through follow-on rounds, as evidenced by portfolio companies progressing to later stages. Recent Activity and Fund Status Recent Investments (2025-2023) : March 2025: Olio Labs, Series A ($4.5M+ raise, participation) January 2025: Bioptimus, Series A (lead investor, $41M+ Series A) September 2023: Sonera, Seed ($6.9M+ raise) March 2023: Bioloomics, Seed ($8.7M raise) September 2022: Harmonic Discovery, Seed ($8M+ raise) Fund Status : Actively deploying with 2 new investments in 2025 (as of March 2025) Geographic Focus Primary investment geography: United States : 10 investments (primarily Bay Area and coastal biotech hubs) France : 1 investment (Bioptimus, Paris-based AI biotech) Singapore : 1 investment (Shiok Meats, precision fermentation) Celestine actively networks in scientific communities including SynBioBeta conferences and academic medical research institutions. Co-investors and Network Boom Capital frequently co-invests with: Founders Fund (early aerospace support) Innovation Endeavors (deep science conviction) Tiger Global Management (follow-ons) Global Health Investment (shared portfolio overlap) Leading scientific institutions (NIH, NSF) Decision Process and Timeline Decision Style : Solo GP model with conviction-based investing Celestine Schnugg maintains direct relationships with founders Frequent participation in scientific conferences and research community Pattern of supporting founders through multiple rounds Typical Timeline : Fast conviction on exceptional technical teams (weeks rather than months) Investment Conviction Pattern Boom Capital demonstrates strong conviction through: First-to-invest pattern : Often earliest institutional capital Follow-on investing : Participates in Series A, B, C rounds for strong portfolio companies Portfolio longevity : Managing companies from pre-seed through Series C Scientific community integration : Embedded in academic and research networks Notable Exits and Achievements Genentech acquisition : Herophilus (portfolio company exit) IPO trajectory : SpaceX (early investment, now major player) Unicorn potential : Multiple portfolio companies approaching unicorn status (Diligent Robots $99.9M+ raised, Bioptimus $76M+ raised) Thesis Anti-Patterns Boom Capital explicitly avoids: Non-scientific founding teams Low-risk, incremental innovation Consumer-focused applications without scientific depth Pure software without biotech, hardware, or aerospace grounding Investment Criteria Summary Stage : Primarily seed with Series A follow-ons Check Size : $50K-$300K initial investment Ideal Company Profile : Deep science founders (PhD-level technical depth) Addressing high-risk, high-impact problems Genomics, machine intelligence, aerospace, new chemistries Clear path to durable IP and defensibility Geographic Preference : US West Coast preferred, international for exceptional teams Timeline to Decision : 2-4 weeks for exceptional teams Investment Climate Notes Boom Capital represents the 'deep science' category within venture, distinct from SaaS/consumer VCs Solo GP structure provides conviction-based investing without committee delays Portfolio demonstrates thesis consistency (12/12 companies align with frontier science mandate) Active in 2025 despite broader venture slowdown, indicating strong fund position